Related Experiment Video
Updated: Feb 13, 2026

Standardization of Basket Use in Sialendoscopy: A Ten-Year Retrospective Study
Published on: June 6, 2025
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A
Sarah Waliany1, Shambo Guha Roy2, Federica Pecci3
11Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, MA.
Background:
Next-generation ALK tyrosine kinase inhibitors (TKIs; eg, alectinib, brigatinib, ceritinib, ensartinib, lorlatinib) are established first-line therapies for patients with ALK fusion-positive (ALK+) advanced/metastatic non-small cell lung cancer (NSCLC). Chemotherapy-with platinum/pemetrexed (PT/Pem) as the preferred regimen-is considered standard next-line therapy. However, limited data exist on outcomes of continuing next-generation ALK TKIs with subsequent PT/Pem after progression on TKI monotherapy.
Patients And Methods:
This multicentered, retrospective study included patients with ALK+ metastatic NSCLC who received PT/Pem alone or with alectinib or lorlatinib (PT/Pem/TKI) after progression on next-generation ALK TKIs. Endpoints included progression-free survival (PFS), overall survival (OS), 12-month cumulative incidence of intracranial progression, and treatment-related adverse events (trAEs).
Results:
We identified 156 patients, of whom 86 received PT/Pem and 70 received PT/Pem/TKI (alectinib: n=23; lorlatinib: n=47). Median PFS was numerically longer with PT/Pem/TKI versus PT/Pem (6.0 vs 3.5 months; hazard ratio [HR], 0.75; P=.11). In 78 patients treated with the current paradigm of first-line next-generation ALK TKIs, PT/Pem/TKI was associated with longer median PFS (6.6 vs 3.5 months; HR, 0.58; P=.042) and longer median OS (16.4 vs 11.4 months; HR, 0.55; P=.041) than PT/Pem alone. Among patients evaluable for intracranial outcomes (n=98), treatment with PT/Pem/TKI was associated with a significantly lower cumulative incidence of intracranial progression compared with PT/Pem alone (18.7% vs 34.0% at 12 months; HR, 0.33; P=.009). In the safety cohort (n=116), grade ≥3 trAEs occurred in 19 of 62 (30.6%) patients treated with PT/Pem, 5 of 18 (27.8%) patients treated with PT/Pem/alectinib, and 18 of 36 (50.0%) patients treated with PT/Pem/lorlatinib. There were no unanticipated safety signals in patients treated with PT/Pem plus alectinib or lorlatinib.
Conclusions:
Among patients who received next-generation ALK TKIs as first-line therapy, continuation of next-generation ALK TKI with PT/Pem led to longer PFS and OS than PT/Pem alone, with no unanticipated toxicities. The modest efficacy of PT/Pem-based regimens overall underscores the need for more effective therapies for TKI-refractory ALK+ NSCLC.
Insights
Continuing next-generation ALK tyrosine kinase inhibitors (TKIs) with platinum/pemetrexed chemotherapy improved progression-free survival and overall survival in advanced ALK-positive non-small cell lung cancer patients. This combination therapy also reduced intracranial progression without new safety concerns.
Area of Science:
- Oncology
- Pharmacology
Background:
- Next-generation ALK tyrosine kinase inhibitors (TKIs) are first-line treatments for ALK-positive advanced/metastatic non-small cell lung cancer (NSCLC).
- Platinum/pemetrexed (PT/Pem) chemotherapy is a standard next-line therapy, but data on continuing TKIs with PT/Pem post-progression are limited.
Purpose of the Study:
- To evaluate the efficacy and safety of continuing next-generation ALK TKIs with PT/Pem chemotherapy compared to PT/Pem alone after TKI progression in ALK+ metastatic NSCLC.
Main Methods:
- Retrospective, multicentered study of 156 patients with ALK+ metastatic NSCLC.
- Patients received either PT/Pem alone or PT/Pem combined with alectinib or lorlatinib (PT/Pem/TKI) after prior next-generation ALK TKI therapy.
- Endpoints included progression-free survival (PFS), overall survival (OS), intracranial progression, and treatment-related adverse events (trAEs).
Main Results:
- Combining PT/Pem/TKI showed numerically longer median PFS (6.0 vs 3.5 months) compared to PT/Pem alone.
- In patients treated with first-line TKIs, PT/Pem/TKI significantly improved median PFS (6.6 vs 3.5 months) and median OS (16.4 vs 11.4 months) versus PT/Pem alone.
- PT/Pem/TKI significantly lowered the 12-month cumulative incidence of intracranial progression (18.7% vs 34.0%) compared to PT/Pem alone, with no unanticipated safety signals.
Conclusions:
- Continuation of next-generation ALK TKIs with PT/Pem chemotherapy improves PFS and OS in ALK+ NSCLC patients progressing on TKI monotherapy.
- This combination strategy demonstrates reduced intracranial progression without significant new toxicities.
- The findings highlight the need for novel therapies for TKI-refractory ALK+ NSCLC, despite the benefits of combined treatment.
More Related Videos
Related Concept Videos
Survey Safety
Self-Efficacy
Positive Regulator Molecules
Household Wiring And Electrical Safety
Position-effect Variegation
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...

